

PRESS RELEASE

Aix-en-Provence, 25 July 2023



Half-year liquidity contract statement

Affluent Medical (Euronext Paris: FR0013333077 – AFME)

Public limited company with a capital of € 30 896 652

Registered office: 320, avenue Archimède Les Pléiades III - Bâtiment B 13100 Aix-en-Provence - France
837 722 560 R.C.S. on the Aix-en-Provence Trade and Companies Register

Under the liquidity contract entered into between Affluent Medical and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th 2023:

- ✓ 124,232 shares
- ✓ € 39,485.10
- ✓ Number of executions on buy side on semester: 245
- ✓ Number of executions on sell side on semester: 129
- ✓ Traded volume on buy side on semester: 35,717 shares for € 50,544.84
- ✓ Traded volume on sell side on semester: 21,629 shares for € 32,173.80

As a reminder:

- the following resources appeared on the last half year statement on 31 December 2022 on the liquidity account:

- ✓ 110,144 shares
- ✓ € 22,697.72
- ✓ Number of executions on buy side on semester: 333
- ✓ Number of executions on sell side on semester: 208
- ✓ Traded volume on buy side on semester: 32,258 shares for € 82,181.80
- ✓ Traded volume on sell side on semester: 13,900 shares for € 33,571.60

- the following resources appeared on the liquidity account when the activity started:

- ✓ 0 shares
- ✓ € 400,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

**Aggregate buy/sell transactions for each trading day**
Period from 02/01/2023 to 30/06/2023

DATE	BUY SIDE			SELL SIDE		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
02/01/2023	4	400	660.00	-	-	-
04/01/2023	-	-	-	1	100	166.00
05/01/2023	-	-	-	2	5	8.30
06/01/2023	1	1	1.66	1	1	1.66
09/01/2023	-	-	-	2	158	267.02
10/01/2023	3	300	501.00	-	-	-
11/01/2023	1	200	334.00	1	137	231.53
12/01/2023	3	400	664.00	-	-	-
16/01/2023	2	200	332.00	2	200	340.00
17/01/2023	3	600	996.00	-	-	-
18/01/2023	1	200	328.00	2	200	338.00
19/01/2023	3	201	337.68	1	1	1.70
20/01/2023	1	1	1.68	1	1	1.68
24/01/2023	4	700	1 169.00	-	-	-
25/01/2023	4	601	997.66	1	1	1.70
30/01/2023	1	200	328.00	1	1	1.67
31/01/2023	1	50	81.50	-	-	-
01/02/2023	2	55	89.65	-	-	-
02/02/2023	-	-	-	1	68	113.56
03/02/2023	-	-	-	2	170	283.90
06/02/2023	-	-	-	2	61	101.87
09/02/2023	3	296	482.48	1	1	1.63
10/02/2023	6	1 000	1 470.00	-	-	-
13/02/2023	-	-	-	5	600	918.00
14/02/2023	4	770	1 185.80	1	200	320.00
15/02/2023	3	400	592.00	-	-	-
16/02/2023	5	524	765.04	-	-	-
17/02/2023	6	876	1 261.44	-	-	-



DATE	BUY SIDE			SELL SIDE		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
20/02/2023	1	200	284.00	-	-	-
21/02/2023	1	1	1.40	5	501	726.45
22/02/2023	3	400	572.00	2	400	592.00
23/02/2023	7	1 200	1 848.00	15	3 006	4 779.54
24/02/2023	12	1 802	2 703.00	1	194	310.40
27/02/2023	3	1 300	1 950.00	2	71	113.60
28/02/2023	2	200	296.00	-	-	-
01/03/2023	4	600	870.00	-	-	-
02/03/2023	6	900	1 260.00	6	1 792	2 795.52
03/03/2023	4	873	1 292.04	-	-	-
06/03/2023	8	1 427	1 997.80	-	-	-
07/03/2023	4	901	1 234.37	2	501	711.42
08/03/2023	4	900	1 215.00	-	-	-
09/03/2023	2	1 000	1 400.00	12	5 508	8 262.00
10/03/2023	1	500	705.00	2	2 000	2 900.00
13/03/2023	1	500	720.00	1	1 000	1 480.00
14/03/2023	3	501	721.44	1	1	1.45
15/03/2023	2	1 001	1 401.40	1	1	1.45
16/03/2023	10	2 775	3 718.50	-	-	-
17/03/2023	1	225	292.50	3	1 001	1 361.36
20/03/2023	1	200	260.00	-	-	-
22/03/2023	1	1	1.31	1	1	1.31
23/03/2023	2	201	261.30	1	1	1.36
24/03/2023	1	1	1.34	2	201	271.35
27/03/2023	2	200	260.00	-	-	-
28/03/2023	1	1	1.35	1	1	1.35
29/03/2023	2	201	261.30	2	101	136.35
30/03/2023	1	1	1.30	1	1	1.30
31/03/2023	1	1	1.31	1	1	1.31
03/04/2023	1	200	250.00	-	-	-



DATE	BUY SIDE			SELL SIDE		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
05/04/2023	1	1	1.24	1	1	1.24
06/04/2023	-	-	-	2	400	532.00
11/04/2023	1	200	260.00	-	-	-
13/04/2023	2	201	251.25	2	200	260.00
14/04/2023	5	1 500	1 815.00	1	1	1.30
17/04/2023	2	200	234.00	1	200	250.00
18/04/2023	1	200	250.00	-	-	-
20/04/2023	1	1	1.25	1	1	1.25
21/04/2023	1	1	1.20	-	-	-
24/04/2023	2	200	242.00	-	-	-
25/04/2023	-	-	-	1	200	250.00
04/05/2023	2	65	81.25	-	-	-
05/05/2023	1	135	168.75	-	-	-
09/05/2023	1	1	1.29	3	401	517.29
10/05/2023	1	199	256.71	-	-	-
11/05/2023	4	400	516.00	2	1 200	1 668.00
12/05/2023	4	800	1 104.00	2	517	739.31
15/05/2023	5	200	280.00	-	-	-
16/05/2023	4	600	816.00	-	-	-
17/05/2023	1	9	11.97	-	-	-
18/05/2023	4	601	793.32	1	1	1.34
19/05/2023	5	600	804.00	-	-	-
22/05/2023	4	800	1 032.00	1	1	1.35
23/05/2023	1	1	1.35	2	50	67.50
25/05/2023	1	43	54.18	-	-	-
26/05/2023	1	1	1.30	1	1	1.30
29/05/2023	2	11	13.86	1	1	1.30
30/05/2023	1	1	1.30	1	1	1.30
31/05/2023	3	348	445.44	1	1	1.34
01/06/2023	3	201	261.30	1	1	1.30



DATE	BUY SIDE			SELL SIDE		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
02/06/2023	1	1	1.30	1	1	1.30
05/06/2023	3	200	260.00	-	-	-
08/06/2023	1	200	260.00	-	-	-
09/06/2023	1	1	1.30	1	1	1.30
12/06/2023	2	100	128.00	-	-	-
13/06/2023	1	100	126.00	-	-	-
15/06/2023	1	1	1.29	1	1	1.29
19/06/2023	1	1	1.29	1	1	1.29
20/06/2023	4	326	407.50	1	1	1.27
21/06/2023	2	76	94.24	1	1	1.25
22/06/2023	1	1	1.25	1	1	1.25
23/06/2023	2	31	37.82	1	1	1.24
26/06/2023	1	170	207.40	2	200	250.00
27/06/2023	1	1	1.24	4	54	67.50
28/06/2023	4	400	484.00	1	1	1.25
30/06/2023	2	400	472.00	-	-	-
TOTAL	245	35 717	50 544.84	129	21 629	32 173.80

**About Affluent Medical**

Affluent Medical is a French MedTech company, founded by Truffle Capital, with the ambition to become a global leader in the treatment of structural heart diseases, which are the world's leading cause of mortality, and urinary incontinence which currently affects one in four adults.

Affluent Medical develops next-generation, mini-invasive, innovative, adjustable, and biomimetic implants to restore critical physiological functions. The product candidates developed by the Company are currently in preclinical and clinical studies.

Subject to raising the necessary funds to finance its strategy and to positive results from ongoing clinical studies, the Company's ambition is to progressively commercialize its products starting in 2025.

For more information: www.affluentmedical.com



PRESS RELEASE

Contacts:

AFFLUENT MEDICAL

Sébastien LADET

Chief Executive Officer

investor@affluentmedical.com

ACTIFIN, financial communications/ financial press relations

Ghislaine GASPARETTO/ Jennifer JULLIA

+33 (0)6 21 10 49 24/ +33 (0)1 56 88 11 19

affluentmedical@actifin.fr / jjullia@actifin.fr

PRIMATICE, public relations France

Thomas ROBOREL de CLIMENS

+33 (0)6 78 12 97 95

thomasdeclimens@primatice.com

MC Services AG

Caroline BERGMANN / Kirsten RÜHL

+49 (0)211 529252 20 / +49 (0)211 529252 16

affluent@mc-services.eu